A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

Upregulation of cytokines and chemokines is a frequent finding in multiple myeloma (MM). CCL3 (also known as MIP-1α) is a pro-inflammatory chemokine, levels of which in the MM microenvironment correlate with osteolytic lesions and tumor burden. CCL3 and its receptors, CCR1 and CCR5, contribute to th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Vallet, Sonia (VerfasserIn) , Pozzi, S. (VerfasserIn) , Patel, K. (VerfasserIn) , Vaghela, N. (VerfasserIn) , Fulciniti, M. T. (VerfasserIn) , Veiby, P. (VerfasserIn) , Hideshima, T. (VerfasserIn) , Santo, L. (VerfasserIn) , Cirstea, D. (VerfasserIn) , Scadden, D. T. (VerfasserIn) , Anderson, K. C. (VerfasserIn) , Raje, N. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 15 March 2011
In: Leukemia
Year: 2011, Jahrgang: 25, Heft: 7, Pages: 1174-1181
ISSN:1476-5551
DOI:10.1038/leu.2011.43
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/leu.2011.43
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/leu201143
Volltext
Verfasserangaben:S Vallet, S Pozzi, K Patel, N Vaghela, MT Fulciniti, P Veiby, T Hideshima, L Santo, D Cirstea, DT Scadden, KC Anderson and N Raje

MARC

LEADER 00000caa a2200000 c 4500
001 1824144970
003 DE-627
005 20230710100800.0
007 cr uuu---uuuuu
008 221201s2011 xx |||||o 00| ||eng c
024 7 |a 10.1038/leu.2011.43  |2 doi 
035 |a (DE-627)1824144970 
035 |a (DE-599)KXP1824144970 
035 |a (OCoLC)1389743118 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Vallet, Sonia  |d 1976-  |e VerfasserIn  |0 (DE-588)105867207X  |0 (DE-627)797396403  |0 (DE-576)414826493  |4 aut 
245 1 2 |a A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function  |c S Vallet, S Pozzi, K Patel, N Vaghela, MT Fulciniti, P Veiby, T Hideshima, L Santo, D Cirstea, DT Scadden, KC Anderson and N Raje 
246 3 3 |a A novel role for CCL3 (MIP-1 alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function 
264 1 |c 15 March 2011 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 01.12.2022 
520 |a Upregulation of cytokines and chemokines is a frequent finding in multiple myeloma (MM). CCL3 (also known as MIP-1α) is a pro-inflammatory chemokine, levels of which in the MM microenvironment correlate with osteolytic lesions and tumor burden. CCL3 and its receptors, CCR1 and CCR5, contribute to the development of bone disease in MM by supporting tumor growth and regulating osteoclast (OC) differentiation. In this study, we identify inhibition of osteoblast (OB) function as an additional pathogenic mechanism in CCL3-induced bone disease. MM-derived and exogenous CCL3 represses mineralization and osteocalcin production by primary human bone marrow stromal cells and HS27A cells. Our results suggest that CCL3 effects on OBs are mediated by ERK activation and subsequent downregulation of the osteogenic transcription factor osterix. CCR1 inhibition reduced ERK phosphorylation and restored both osterix and osteocalcin expression in the presence of CCL3. Finally, treating SCID-hu mice with a small molecule CCR1 inhibitor suggests an upregulation of osteocalcin expression along with OC downregulation. Our results show that CCL3, in addition to its known catabolic activity, reduces bone formation by inhibiting OB function, and therefore contributes to OB/OC uncoupling in MM. 
650 4 |a Chemokines 
650 4 |a Metabolic bone disease 
650 4 |a Myeloma 
700 1 |a Pozzi, S.  |e VerfasserIn  |4 aut 
700 1 |a Patel, K.  |e VerfasserIn  |4 aut 
700 1 |a Vaghela, N.  |e VerfasserIn  |4 aut 
700 1 |a Fulciniti, M. T.  |e VerfasserIn  |4 aut 
700 1 |a Veiby, P.  |e VerfasserIn  |4 aut 
700 1 |a Hideshima, T.  |e VerfasserIn  |4 aut 
700 1 |a Santo, L.  |e VerfasserIn  |4 aut 
700 1 |a Cirstea, D.  |e VerfasserIn  |4 aut 
700 1 |a Scadden, D. T.  |e VerfasserIn  |4 aut 
700 1 |a Anderson, K. C.  |e VerfasserIn  |4 aut 
700 1 |a Raje, N.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Leukemia  |d London : Springer Nature, 1997  |g 25(2011), 7, Seite 1174-1181  |h Online-Ressource  |w (DE-627)32046699X  |w (DE-600)2008023-2  |w (DE-576)094139733  |x 1476-5551  |7 nnas  |a A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function 
773 1 8 |g volume:25  |g year:2011  |g number:7  |g pages:1174-1181  |g extent:8  |a A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function 
856 4 0 |u https://doi.org/10.1038/leu.2011.43  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.nature.com/articles/leu201143  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20221201 
993 |a Article 
994 |a 2011 
998 |g 105867207X  |a Vallet, Sonia  |m 105867207X:Vallet, Sonia  |d 910000  |d 910100  |e 910000PV105867207X  |e 910100PV105867207X  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1824144970  |e 4222627690 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 01.12.2022"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"1824144970","titleAlt":[{"title":"A novel role for CCL3 (MIP-1 alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function"}],"person":[{"given":"Sonia","family":"Vallet","role":"aut","roleDisplay":"VerfasserIn","display":"Vallet, Sonia"},{"roleDisplay":"VerfasserIn","display":"Pozzi, S.","role":"aut","family":"Pozzi","given":"S."},{"family":"Patel","given":"K.","display":"Patel, K.","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Vaghela, N.","role":"aut","family":"Vaghela","given":"N."},{"given":"M. T.","family":"Fulciniti","role":"aut","roleDisplay":"VerfasserIn","display":"Fulciniti, M. T."},{"given":"P.","family":"Veiby","role":"aut","display":"Veiby, P.","roleDisplay":"VerfasserIn"},{"given":"T.","family":"Hideshima","role":"aut","display":"Hideshima, T.","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Santo, L.","given":"L.","family":"Santo"},{"roleDisplay":"VerfasserIn","display":"Cirstea, D.","role":"aut","family":"Cirstea","given":"D."},{"given":"D. T.","family":"Scadden","role":"aut","display":"Scadden, D. T.","roleDisplay":"VerfasserIn"},{"family":"Anderson","given":"K. C.","display":"Anderson, K. C.","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Raje, N.","given":"N.","family":"Raje"}],"title":[{"title_sort":"novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function","title":"A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function"}],"physDesc":[{"extent":"8 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedKey":"1997"}],"id":{"zdb":["2008023-2"],"eki":["32046699X"],"issn":["1476-5551"]},"note":["Gesehen am 15.03.04"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast functionLeukemia","recId":"32046699X","language":["eng"],"pubHistory":["Nachgewiesen 11.1997 -"],"part":{"extent":"8","text":"25(2011), 7, Seite 1174-1181","volume":"25","pages":"1174-1181","issue":"7","year":"2011"},"title":[{"title":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia"}]}],"name":{"displayForm":["S Vallet, S Pozzi, K Patel, N Vaghela, MT Fulciniti, P Veiby, T Hideshima, L Santo, D Cirstea, DT Scadden, KC Anderson and N Raje"]},"origin":[{"dateIssuedDisp":"15 March 2011","dateIssuedKey":"2011"}],"id":{"eki":["1824144970"],"doi":["10.1038/leu.2011.43"]}} 
SRT |a VALLETSONINOVELROLEF1520